Anika Therapeutics ANIK Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.61M+13.2% | $30.62M— | $27.82M-28.2% | $28.22M-32.7% | $26.17M-35.4% | ||
| $29.61M+13.2% | $30.62M— | $27.82M-28.2% | $28.22M-32.7% | $26.17M-35.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Anika Therapeutics's revenue?
- Anika Therapeutics (ANIK) generated $116.3M in revenue over the trailing twelve months, up 8.8% year over year.
- Is Anika Therapeutics profitable?
- Anika Therapeutics is not currently profitable: it reported a net loss of $11.4M over the trailing twelve months, a -9.8% net margin.
- Where does Anika Therapeutics's income statement data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
